Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cells expressing a tyrosine hydroxylase (TH) cDNA under control of the promoter of the human glial fibrillary acidic protein (GFAP) gene were tested for therapeutic efficacy in a rat model of Parkinson's disease. The GFAP gene encodes an intermediate filament protein found almost exclusively in astrocytes. Its promoter is of interest for gene therapy as it is expressed in astrocytes throughout postnatal life and is upregulated in response to almost any damage to the central nervous system, including Parkinson's disease. We previously showed that a line of C6 rat glioma cells that expresses a GFAP-TH transgene, C6-THA, displays increased transgene activity when differentiated by forskolin treatment. Accordingly, the effects were investigated of implantation of both undifferentiated and differentiated C6-THA cells into the striatum of rats that had been lesioned with 6-hydroxydopamine. Implantation of either cell type produced significant behavioral recovery one week after transplantation, as judged by the turning response to apomorphine. At two and three weeks after transplantation, the behavioral effect of the undifferentiated cells was no longer statistically significant, whereas that for the forskolin-differentiated cells remained robust. Transgenic TH mRNA and protein could be detected in implants of both cell types, and in agreement with the behavioral results, levels were higher for the differentiated C6-THA cells than for the undifferentiated cells. These results indicate that the GFAP promoter is sufficiently active to enable production of therapeutic levels of dopamine from a GFAP-TH transgene, and suggest the use of astrocytes for gene therapy for Parkinson's disease. They also show that beneficial modifications of cells produced by treatment while in culture may be maintained following implantation.
 ...
PMID:Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene. 1046 75

In order to study neuronal death in Parkinson's disease, neurons of the substantia nigra, pars compacta in rats were exposed to elevated levels of glutamate and decreased levels of energy in vivo and consequences for behavior and neuronal morphology were studied. Thus, repeated local injections (9x) of the glutamate uptake inhibitor L- threo-hydroxyaspartate (L-THA; 833 microM in 0.3 microl) in the presence or absence of the succinate dehydrogenase inhibitor malonate (25 mM in 0.3 microl) were applied during three weeks. 24 h after injection, rigidity and catalepsy were measured, as well as, at the end of the three week period, locomotion, rearing and exploratory behavior. Thereafter, the cytoarchitecture of the substantia nigra, pars compacta of the brains of these rats was described. The L-THA plus malonate injected rats did not differ in their behavior from carrier injected rats, except for rigidity: their scores were higher than that of carrier and L-THA injected rats (P < 0.05), while L-THA injected rats did not differ from carrier injected controls. Observations on cresyl violet sections revealed, that, although many neurons with a shrunken nucleolus and faintly stained cytoplasm were present in both L-THA and L-THA plus malonate treated rats, the ventral edge of the substantia nigra, pars compacta containing modified cells was longer in L-THA plus malonate than in L-THA injected rats (P < 0.05). This indicates, that a minimum amount of damage to neurons in the ventral part of the substantia nigra, pars compacta might be required for the expression of rigidity.
 ...
PMID:Local application of L- threo-hydroxyaspartate and malonate in rats in vivo induces rigidity and damages neurons of the substantia nigra, pars compacta. 1237 61

Glioma cell line C6, transfected with tyrosine hydroxylase (TH) cDNA under the control of the glial fibrillary acid protein promoter (C6-THA cells), elicited a reduction in the apomorphine-induced turning behavior when they are implanted in Parkinson's disease models. Nevertheless, dopamine (Da) release has not been explicitly demonstrated nor has a possible mechanism of release been implicated. In this study, the in vitro Da release by C6 and C6-THA cells after chemical stimulation with KCl or glutamate was quantified using HPLC. Modifications in intracellular calcium levels in response to KCl stimulation and participation of Da receptor-mediated feedback in calcium regulation were also studied using FLUO 3 as a calcium concentration indicator. C6-THA cells release dopamine in basal conditions, and increase its release after KCl or glutamic acid stimulation. In a fraction of C6 and C6-THA cells, a transient intracellular calcium increase was observed after KCl stimulation, but C6-THA cells demonstrated a faster rate of calcium removal. C6 cells express mRNA from all five subtypes of Da receptors as demonstrated by real time PCR. D1 receptors were most abundant in C6 cells and its expression was further increased in C6-THA cells. Blocking D1-like receptors in C6-THA cells with the specific antagonist drug SCH-23390 induced a decrease in intracellular calcium removal rate, resembling non-manipulated C6 cells' calcium clearance. Da release by C6-THA cells could be related to calcium dependent mechanisms. Furthermore, production of Da by C6-THA cells seems to upregulate the expression of D1 receptors' mRNA.
 ...
PMID:Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells. 1768 96